Last reviewed · How we verify
NCT04888286: AIBT_DSAs
DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
trial in Hematologic Diseases in 912 participants. Completed in 22 June 2021.
22 June 2021
Quick facts
| Lead sponsor | Gruppo Italiano Trapianto di Midollo Osseo |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 912 |
| Start date | 15 October 2018 |
| Primary completion | 22 June 2021 |
| Estimated completion | 22 June 2021 |
| Sites | 25 locations across Italy |
Conditions studied
- Hematologic Diseases — all drugs for Hematologic Diseases →
- Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →
Sponsor
Gruppo Italiano Trapianto di Midollo Osseo — full company profile →
Who can join
Eligibility, any sex, with Hematologic Diseases or Stem Cell Transplant Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective observational multicentric, spontaneous non-interventional non-pharmacological Italian study. The primary objective is analysis of Anti-HLA antibodies and DSAs searching and monitoring activities in haematological adult and paediatric patients undergoing allo-HSCT from January 2014 to June 2017. This study will evaluate approximately 1000 subjects (with competitive enrolment) from GITMO investigational centers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04888286
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematologic Diseases
Currently open trials in the same condition.
- NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT05414045 — Autologous Testicular Tissue Transplantation · NA · recruiting
- NCT06613425 — Clinical Study of Combined Platelet Transfusion · Phase 4 · recruiting
- NCT06271252 — A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · Phase 1 · recruiting
Other Gruppo Italiano Trapianto di Midollo Osseo trials
Trials by the same sponsor.
- NCT06790680 — GITMO AML/MDS-Relapse Registry Study · completed
- NCT04506320 — Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma · completed
- NCT04412811 — Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT · completed
- NCT03270748 — Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies · Phase 2 · completed
- NCT04476199 — Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04888286 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gruppo Italiano Trapianto di Midollo Osseo
- Last refreshed: 25 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04888286.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing